Note: If you attended the live CE activity AND received CE credit (i.e. a pharmacist CE statement of credit with ACPE UAN 0221-9999-19-198-L01-P), you are NOT allowed to also receive credit for this home-study on-demand web activity.
|A product of the Society of Infectious Diseases Pharmacists Education Center (SIDPEC)|
C. difficile infection (CDI) recurs in nearly 25% of patients. Ideally, the primary treatment goal should be reduction of recurrence. However, in patients experiencing recurrence, the goal shifts to treating therapyresistance. This is especially important given that the risk of recurrence increases after each unsuccessful treatment. This activity will address gaps identified by prior activity feedback and literature review to address patient education and counseling reminders to reduce the risk of recurrence, patient-specific risk factors for recurrent CDI, recommended and emerging treatments for recurrent CDI, and factors in health-system reduction of rCDI. A special focus on techniques to address recurrence and spread will be reinforced with case studies.
The target audience for this activity includes pharmacists and nurses. At the completion of this activity, the participant will be able to:
- Outline patient risk factors for recurrent C. difficile infections and strategies to reduce recurrence rates.
- Compare and contrast recommended and emerging treatment options for recurrent C. difficile infections.
- Describe techniques for staff and patient education to reduce the recurrence and spread of C. difficile infections.
- Discuss financial and reimbursement issues related to hospital C. difficile infection (CDI) rates and pay for performance measures.
Nicholas S. Britt, PharmD, MS, BCPS, BCIDP
Assistant Professor, Pharmacy Practice and Internal Medicine
University of Kansas, Schools of Pharmacy and Medicine
Kansas City, KS
Maggie Reavis BSN, RN, CIC
Infection Control Nurse II
Infection Prevention and Control
The University of Kansas Health System
Kansas City, KS
Release Date: 8-1-2019
Expiration Date: 10-28-2020
This activity is jointly provided by ProCE, Inc. and the Society of Infectious Diseases Pharmacists. ProCE, Inc. is accredited by the Accreditation Council for Pharmacy Education as a provider of continuing pharmacy education. ACPE Universal Activity Number 0221-9999-19-198-H01-P has been assigned to this live knowledge-based activity. This activity is approved for 1.0 contact hours (0.1 CEU) in states that recognize ACPE providers. The activity is provided at no cost to participants. Participants must complete the online post-test and activity evaluation to receive pharmacy CE credit. No partial credit will be given. Statements of completion will be issued online at www.ProCE.com, and proof of completion will be posted in NABP CPE Monitor profiles.
This CE activity is jointly provided by ProCE, Inc. and Wild Iris Medical Education, Inc. This activity provides 1.0 contact hour of nurse CE credit.
Wild Iris Medical Education, Inc. is accredited as a provider of continuing nursing education by the American Nurses Credentialing Center's Commission on Accreditation.
It is the policy of ProCE, Inc. to ensure balance, independence, objectivity and scientific rigor in all of its continuing education activities. Faculty must disclose to participants any significant financial interest or affiliation with companies that manufacture or market products discussed during their presentation. Dr. Britt has received research grant support from Merck. Ms. Reavis has no relevant commercial or financial relationships to disclose. Potential conflict of interest was resolved with an outside peer review.
This activity is supported by an educational grant from Merck.
The material presented in this CE activity does not reflect the views of ProCE, Inc. or the commercial sponsor. These materials may discuss uses and dosages for therapeutic products, processes, procedures and inferred diagnoses that have not been approved by the United States Food and Drug Administration. A qualified health care professional should be consulted before using any therapeutic product discussed. All readers and continuing education participants should verify all information and data before treating patients or employing any therapies described in this continuing education activity.